Researchers are excited about the medication , a novel dual agonist showing significant outcomes in early trials for body loss . It acts by impacting both pathways : GLP-1 and GIP, which , when https://umaryktb173817.spintheblog.com/41105256/the-new-prospect-for-weight-management